[ A22-88] Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2022
Project no.:
A22-88
Commission:
Commission awarded on 22.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Haematology
Treatment of fibroblast growth factor 23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localized in patients aged 1 year and older
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-12 | Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-11 | Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G20-27 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G19-15 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| G18-05 | Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |